HONG KONG – Carsgen Therapeutics Ltd. and Shanghai Cancer Institute entered a five-year research and development agreement for Carsgen's chimeric antigen receptors T-cell (CAR-T) cancer immunotherapeutic candidates. The partners will work together to discover and develop CAR-T candidates as well as next-generation CAR-T drug candidates.